Ted Buchan & Co Makes New $1.78 Million Investment in Eli Lilly and Company (NYSE:LLY)

Ted Buchan & Co purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,966 shares of the company’s stock, valued at approximately $1,780,000. Eli Lilly and Company comprises 1.0% of Ted Buchan & Co’s holdings, making the stock its 25th biggest holding.

A number of other institutional investors have also recently bought and sold shares of LLY. J. W. Coons Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 4.0% during the fourth quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after acquiring an additional 90 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Eli Lilly and Company by 27.9% during the fourth quarter. Jones Financial Companies Lllp now owns 9,024 shares of the company’s stock worth $5,260,000 after acquiring an additional 1,967 shares during the period. CWA Asset Management Group LLC boosted its holdings in shares of Eli Lilly and Company by 32.7% during the fourth quarter. CWA Asset Management Group LLC now owns 3,272 shares of the company’s stock worth $1,907,000 after acquiring an additional 807 shares during the period. Belpointe Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 3.5% during the fourth quarter. Belpointe Asset Management LLC now owns 5,175 shares of the company’s stock worth $3,017,000 after acquiring an additional 177 shares during the period. Finally, ROI Financial Advisors LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $9,181,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LLY. Bank of America boosted their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Barclays boosted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $885.56 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $841.64 billion, a P/E ratio of 130.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The firm’s fifty day simple moving average is $896.50 and its two-hundred day simple moving average is $844.99. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 52,369 shares of the stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $915.18, for a total transaction of $47,927,061.42. Following the transaction, the insider now owns 97,247,403 shares of the company’s stock, valued at approximately $88,998,878,277.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 364,810 shares of company stock valued at $339,366,198 in the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.